



FOR IMMEDIATE RELEASE

Genentech Acquires the OriGene TrueClone™ Collection

Rockville, MD. March 28, 2006 – OriGene Technologies Inc. announced that Genentech (NYSE DNA) has purchased their TrueClone™ Collection of full-length human cDNAs suitable for transfection and direct in vitro expression.

Although there are many different efforts to collect every human full-length cDNA clones, OriGene's Trueclone Collection is the most comprehensive to date. OriGene cDNA clones are expression-ready, authentic full-length cDNA plasmids for use in target and lead identification and validation. The cDNAs allow scientists to easily query the roles of genes in disease phenotypes and pathways. These cDNA clones have been used by most leading pharmaceutical companies and research institutes providing numerous discoveries. One example of the power of broad collections of cDNAs in uniform expression systems can be seen in Proc. Natl. Acad. Sci., 2005, pp 1927-32.

"OriGene's mission is to build the most comprehensive collection of human full-length cDNAs in expression-ready vectors and to make this collection available to all researchers for systematic studies of human gene functions," said Karl Kovacs PhD, Vice President of Alliance Management at OriGene. "We are glad to see our clones involved in the highly innovative research at Genentech".

About OriGene Technologies

OriGene provides innovative technologies for large-scale gene function analyses. OriGene's flagship product is the TrueClone Collection, a searchable source of over 24,000 human full-length cDNA clones suitable for transfection and protein expression. More information about OriGene Technologies, the GFC-Arrays and their other products can be found at the company's web site <http://www.origene.com>.

For additional information regarding this announcement, please contact:

Rich Hamer, Ph.D.
Business Development
OriGene Technologies
(301) 802-2269
rhamer@origene.com